230 related articles for article (PubMed ID: 33845873)
1. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
3. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
4. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
[TBL] [Abstract][Full Text] [Related]
5. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Expression of
de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
[TBL] [Abstract][Full Text] [Related]
7. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
8. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Drusbosky LM; Singh NK; Hawkins KE; Salan C; Turcotte M; Wise EA; Meacham A; Vijay V; Anderson GG; Kim CC; Radhakrishnan S; Ullal Y; Talawdekar A; Sikora H; Nair P; Khanna-Gupta A; Abbasi T; Vali S; Guha S; Farhadfar N; Murthy HS; Horn BN; Leather HL; Castillo P; Tucker C; Cline C; Pettiford L; Lamba JK; Moreb JS; Brown RA; Norkin M; Hiemenz JW; Hsu JW; Slayton WB; Wingard JR; Cogle CR
Blood Adv; 2019 Jun; 3(12):1837-1847. PubMed ID: 31208955
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
10. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
11. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
12. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
13. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
[TBL] [Abstract][Full Text] [Related]
14. Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis.
Huang X; Wang X
Medicine (Baltimore); 2020 Aug; 99(34):e21900. PubMed ID: 32846854
[TBL] [Abstract][Full Text] [Related]
15. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
16. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
Sakhdari A; Class C; Montalban-Bravo G; Sasaki K; Bueso-Ramos CE; Patel KP; Routbort MJ; Loghavi S; Ok CY; Quesada A; Khoury JD; Konoplev SN; Kantarjian HP; Garcia-Manero G; Medeiros LJ; Kanagal-Shamanna R
Mod Pathol; 2022 Sep; 35(9):1212-1219. PubMed ID: 35504958
[TBL] [Abstract][Full Text] [Related]
18. EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.
Wang X; Dai H; Wang Q; Wang Q; Xu Y; Wang Y; Sun A; Ruan J; Chen S; Wu D
PLoS One; 2013; 8(4):e61341. PubMed ID: 23613835
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.
Ball S; Aguirre LE; Jain AG; Ali NA; Tinsley SM; Chan O; Kuykendall AT; Sweet K; Lancet JE; Sallman DA; Hussaini MO; Padron E; Komrokji RS
Leuk Res; 2023 Jan; 124():106999. PubMed ID: 36542963
[TBL] [Abstract][Full Text] [Related]
20. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
